The Matthew Larson Foundation for Pediatric Brain Tumors Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2016
NCT02962167
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

attenuated measles vaccine - Edmonston strain (rubeovax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Measles (Phase 1)

Medulloblastoma (Phase 1)

Rhabdoid Tumor (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1